

NALIRIFOX Compared With FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma: An Overall Survival External Control Arm Study

Comprehensive Change Log: Original PDF vs Final PDF

Note: Page numbers are based on the extracted PDF pagination. Exact quoted text is limited to the portions that changed.

Change #	Page #	Section	Original Text	Final Text	Classification
1	1	Abstract	...benefit of NALIRIFOX vs mFOLFIRINOX...	...benefit of NALIRIFOX vs FOLFIRINOX and mFOLFIRINOX...	Substantive
2	1	Abstract	The mFOLFIRINOX cohorts were aligned...	The FOLFIRINOX and mFOLFIRINOX cohorts were aligned...	Editorial
3	2	Introduction	dosing regimen (mFOLFIRINOX)	dosing regimen modified FOLFIRINOX (mFOLFIRINOX)	Editorial
4	2	Introduction	added to 1L mPDAC treatment armamentarium	added to the 1L mPDAC treatment armamentarium	Copyedit
5	2	Data Sources	A total of 770 participants were randomized	In total, 770 participants were randomized	Copyedit
6	2	Data Sources	liposomal irinotecan plus oxaliplatin plus 5-FU/LV	liposomal irinotecan + oxaliplatin + 5-FU/LV	Formatting
7	2	Data Sources	Participants were followed every 2 months	Participants were followed up every 2 months	Copyedit
8	3	Study Population	received a modified FOLFIRINOX (mFOLFIRINOX) regimen	received a mFOLFIRINOX regimen	Terminology
9	3	Study Population	the "all-comer cohort"	the "all-comer cohort"	Formatting

10	3	Outcomes	Overall survival during the study period	OS during the study period	Terminology
11	3	Statistical Analysis	logistic regression	logistic regression model	Editorial
12	3	Statistical Analysis	comparative analyses.	comparative analyses. Through IPTW...	Flow/Copyedit
13	3	Results Metrics	Hazard ratios and 95% CI	HRs and 95% CI	Terminology
14	6	OS Results	11.7; 10.5-13.0	(11.7 [10.5-13.0])	Formatting
15	6	OS Results	9.0 (7.3-11.1)	(9.0 [7.3-11.1])	Formatting
16	7	Discussion	received full or modified FOLFIRINOX treatment	received full or mFOLFIRINOX treatment	Terminology
17	7	Discussion	aligned the real-world mFOLFIRINOX cohorts	aligned the real-world FOLFIRINOX and mFOLFIRINOX cohorts	Substantive
18	7-8	Limitations	individuals in the mFOLFIRINOX cohorts	individuals in the FOLFIRINOX and mFOLFIRINOX cohorts	Substantive
19	8	Limitations	inclusion in the mFOLFIRINOX study cohorts	inclusion in the FOLFIRINOX and mFOLFIRINOX study cohorts	Substantive
20	8	Limitations	real-world mFOLFIRINOX cohorts	real-world FOLFIRINOX and mFOLFIRINOX cohorts	Substantive
21	8	Index Dates	for the NALIRIFOX; date of first FOLFIRINOX administration for the mFOLFIRINOX	for the NALIRIFOX and date of first FOLFIRINOX administration for the FOLFIRINOX and mFOLFIRINOX cohorts	Substantive
22	8	Treatment Exposure	all patients in the mFOLFIRINOX cohorts	all patients in the FOLFIRINOX and mFOLFIRINOX cohorts	Substantive
23	8	Regional Differences	between the 2 study cohorts;	between the 2 study cohorts.	Copyedit
24	8	Generalizability	receiving 1L mFOLFIRINOX regimens	receiving 1L FOLFIRINOX or mFOLFIRINOX regimens	Substantive

25	8	Conclusion	longer on 1L NALIRIFOX treatment than on 1L mFOLFIRINOX	longer on 1L NALIRIFOX treatment than on 1L FOLFIRINOX or mFOLFIRINOX	Major substantive
26	8	Conclusion	comparative efficacy/effectiveness of 1L NALIRIFOX and mFOLFIRINOX	comparative efficacy/effectiveness of both 1L NALIRIFOX and mFOLFIRINOX	Editorial
27	8	Conclusion	in ecology of care	in the ecology of care	Copyedit
28	8	Key Clinical Summary	≈ symbols	~ symbols	Formatting
29	9	Disclosures	George Kim disclosure omitted	Added: G.K. has nothing to disclose.	Disclosure
30	9	Disclosures Order	E.M. disclosure listed first	D.K. disclosure listed first; G.K. added	Disclosure formatting
31	9	Reference 3	doi ending ...987556	doi ending ...987558	Reference correction
32	9	Reference 6	Abraxane. Prescribing information. Bristol Myers Squibb; 2022.	US FDA Abraxane prescribing information. Revised 2020.	Reference update
33	10	Reference 9	141-48	141-148	Reference formatting
34	10	Reference 17	NALIRIFOX versus	NALIRIFOX versus	Copyedit
35	10	Reference 20	considerations for the design...	Considerations for the design...	Capitalization